Corporate Information

Company Name Eisai Co., Ltd.
Date Established December 6, 1941
Head Office 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Telephone 81-3-3817-3700
Representatives Haruo Naito, Representative Corporate Officer and CEO
Yasushi Okada, Representative Corporate Officer, COO and Industry Affairs
Capital 44,986 million Yen (as of March 31, 2019)
Scope of Business Research and development, manufacture, sale and import and export of pharmaceuticals
Employees Consolidated : 10,683
Non-Consolidated : 3,140 (as of March 31, 2019)
Production Plants Kawashima Plant (Gifu Prefecture)
Kashima Plant (Ibaraki Prefecture)
Eisai Manufacturing Ltd. (U.K.)
Eisai China Inc. Suzhou Plant (China)
Eisai (Liaoning) Pharmaceutical Co., Ltd. Benxi Plant (China)
Eisai Pharmaceuticals India Pvt. Ltd. (India), etc.
Laboratories Tsukuba Research Laboratories (Ibaraki Prefecture)
Kawashima Plant (Gifu Prefecture)
Kashima Business Office (Ibaraki Prefecture)
KAN Research Institute, Inc. (Hyogo Prefecture)
Eisai Center for Genetics Guided Dementia Discovery (G2D2) (U.S.A.)
Exton Site (U.S.A.)
H3 Biomedicine Inc. (U.S.A.)
Hatfield Research Institute (U.K.), etc.
Overseas Sales Offices Eisai Inc. (U.S.A.)
Eisai Ltd. (U.K.)
Eisai GmbH (Germany)
Eisai S.A.S. (France)
Eisai China Inc. (China)
Eisai Korea Inc. (South Korea), etc.

Stock Information

Fiscal Year End March 31
Record Date for Dividend Year-end dividend - March 31
Interim dividend - September 30
Annual Shareholders' Meeting June
Stock Exchange Listings Tokyo Stock Exchange
Stock Trading Unit 100 shares
Ticker Code 4523